Advances in (177)Lu-PSMA and (225)Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer

For patients with metastatic castration-resistant prostate cancer (mCRPC), the survival benefit of classic treatment options with chemotherapy and drugs targeting androgen signaling is limited. Therefore, beta and alpha radionuclide therapy (RNT) have emerged as novel treatment options for patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Ling, Sui Wai, de Blois, Erik, Hooijman, Eline, van der Veldt, Astrid, Brabander, Tessa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607057/
https://www.ncbi.nlm.nih.gov/pubmed/36297601
http://dx.doi.org/10.3390/pharmaceutics14102166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607057/
https://www.ncbi.nlm.nih.gov/pubmed/36297601
http://dx.doi.org/10.3390/pharmaceutics14102166

Ejemplares similares